High-Purity Research Peptides with Free Shipping Within the U.S.
AOD9604
AOD9604
$65.00
Quantity
Description
AOD9604, known as "Anti-Obesity Drug 9604," stands out as a key achievement in targeted metabolic studies. Designed to capture solely the fat-releasing effects of human growth hormone, this peptide segment delivers focused lipid breakdown without the broader hormonal impacts of complete HGH. It's like pulling out only the "fat-reduction section" from the full spectrum of growth hormone activities.
AOD9604's appeal lies in its evolution from clinical trial prospect to GRAS-approved nutraceutical component. Even with varied trial outcomes, its outstanding safety record and distinctive mode of operation maintain its relevance in fat metabolism research, providing investigators a clean method to explore lipolysis free from full hormone-related challenges.
Additional Information
Weight: 0.08 lbs
Dimensions: 0.87 × 1.18 × 0.87 in
Size: 10mg
This product is intended solely for research purposes. It is not authorized for use in humans or animals and should only be handled by trained personnel in appropriate laboratory settings.
Highlights
Structural Properties
Appearance: White to slightly off-white freeze-dried powder
Solubility: Easily dissolves in water
Storage Conditions: Store refrigerated at 36–46 °F (2–8 °C)
Stability: Highly stable due to disulfide bond
Biochemical Profile
Chemical Formula: C₇₈H₁₂₃N₂₃O₂₃S₂
Molecular Weight: 1815.12 g/mol
Origin: HGH Fragment 176-191 + Tyrosine
Structure: Modified peptide with disulfide bridge
Biological Mechanism
AOD9604 utilizes a distinctive approach that specifically focuses on fat metabolism:
Key Mechanisms
Beta-3 Receptor Stimulation
Boosts receptors responsible for fat destruction and calorie burning
Fat Breakdown Activation
Converts accumulated fats into usable energy components
Fat Formation Blockade
Prevents development of new fat deposits and storage
Independent from HGH Pathway
Functions through proprietary mechanism, not hormone receptors
Metabolic Benefits
No IGF-1 Increase
Eliminates side effects linked to complete growth hormone
Blood Sugar Stable
Preserves normal glucose levels and insulin function
Precise Targeting
Affects only fat areas without hormone disruption
Research Highlights
Scientific and clinical studies have identified multiple uses for AOD9604:
Clinical Study Findings
Six human trials confirmed:
• Outstanding safety record with few adverse reactions
• 1.8-2.8kg body weight reduction over 12 weeks
• No immune system activation or antibodies
• No changes in IGF-1 levels or sugar processing
• Approved GRAS status for supplement applications
Fat Metabolism Effects
Lab investigations demonstrate focused action:
• Increased fat breakdown in storage tissues
• Decreased fat creation and deposit buildup
• Muscle tissue protection maintained
• No influence on hunger signals
• Anti-inflammatory cardiovascular effects
Joint Support Potential
Preliminary studies show promise for:
• Osteoarthritis pain and symptom relief
• Cartilage repair capabilities
• Lower inflammation in joint tissues
• Improved movement in test animals
• Complements hyaluronic acid therapies
Heart Health Advantages
Research suggests benefits including:
• Optimized cholesterol patterns
• Lower heart disease indicators
• Improved blood vessel performance
• No negative heart impacts
• Anti-inflammatory cardiovascular effects
Possible Research-Related Effects
AOD9604 is characterized by an outstanding tolerability profile:
Minimal Adverse Events
Consistently well‑tolerated across clinical evaluations.
Local Administration Effects
Occasional mild redness or irritation at injection sites observed.
Absence of Systemic Impact
No hormonal or metabolic disturbances reported.
No Antibody Formation
Studies show no immune response triggered.
GRAS Classification
Recognized as safe under established guidelines.
Extended Safety Record
Long‑term studies reveal no adverse outcomes.
The strong tolerability profile supports its GRAS recognition in nutraceutical applications.
Important Information: This material is restricted to experimental laboratory work and must not be used in humans or animals.
References
Growth hormone secretagogues and metabolic effects: Focus on AOD9604. Metabolism, 2023.
Detection and in vitro metabolism of AOD9604. Drug Test Anal, 2016.
Peptide therapeutics for cartilage regeneration and osteoarthritis treatment. Front Pharmacol, 2022.
Anti-obesity drug discovery: advances and challenges in targeting metabolic pathways. Nat Rev Drug Discov, 2021.
Therapeutic peptides for fat loss: Current status and future directions. BioDrugs, 2020.
About Us
Zenergen Research Products is committed to supplying high-purity peptides intended for research use, with an emphasis on quality control and dependable delivery.
Contact Us
Copyright© 2026 Zenergen Research - All Rights Reserved.